Medical care cost of patients with prostate cancer (Q39717558)

14 September 2017

Medical care cost of patients with prostate cancer (English)

1 reference

14 September 2017

Ravishankar Jayadevappa

series ordinal

1

object named as

Ravishankar Jayadevappa

1 reference

14 September 2017

2

Sumedha Chhatre

1 reference

14 September 2017

Mark Weiner

3

1 reference

PubMed ID

15907714

14 September 2017

Bernard S Bloom

series ordinal

4

1 reference

PubMed ID

15907714

14 September 2017

S Bruce Malkowicz

series ordinal

5

1 reference

14 September 2017

1 May 2005

1 reference

14 September 2017

1 reference

14 September 2017

23

1 reference

14 September 2017

3

1 reference

14 September 2017

155-162

1 reference

14 September 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Controversy in managing patients with prostate cancer. Banish dogma, get more data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The economic costs of early stage prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

An economic overview of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The economic burden of prostate cancer, California, 1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Perioperative costs and charges of prostate brachytherapy and prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Quality of Life and Economic Considerations in the Management of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Stage at presentation and survival of white and black patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Race, prostate cancer survival, and membership in a large health maintenance organization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The impact of co-morbidity on life expectancy among men with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Racial differences in the cost of treating men with early-stage prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Sequence effects, health profiles, and the QALY model: in search of realistic modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Trends and black/white differences in treatment for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Racial/ethnic disparities in the treatment of localized/regional prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Evaluation of direct medical costs related to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Follow-up costs after external radiation for low risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

A comparison of two methods for estimating the technical costs of external beam radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Cost comparison of radical prostatectomy and transperineal brachytherapy for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Costs of prostate cancer, metastatic to the bone, in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Radical perineal prostatectomy: cost efficient, outcome effective, minimally invasive prostate cancer management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Advanced prostate cancer: course, care, and cost implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2004.11.006

1 reference

14 September 2017

1 reference

PubMed ID

15907714